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BACKGROUND

Sotorasib showed anticancer activity in patients with KRAS p.G12C–mutated advanced solid tumors in a phase 1 study, and particularly promising anticancer
activity was observed in a subgroup of patients with non–small-cell lung cancer
(NSCLC).
METHODS

In a single-group, phase 2 trial, we investigated the activity of sotorasib, administered orally at a dose of 960 mg once daily, in patients with KRAS p.G12C–
mutated advanced NSCLC previously treated with standard therapies. The primary
end point was objective response (complete or partial response) according to independent central review. Key secondary end points included duration of response,
disease control (defined as complete response, partial response, or stable disease),
progression-free survival, overall survival, and safety. Exploratory biomarkers were
evaluated for their association with response to sotorasib therapy.
RESULTS

Among the 126 enrolled patients, the majority (81.0%) had previously received
both platinum-based chemotherapy and inhibitors of programmed death 1 (PD-1) or
programmed death ligand 1 (PD-L1). According to central review, 124 patients had
measurable disease at baseline and were evaluated for response. An objective response was observed in 46 patients (37.1%; 95% confidence interval [CI], 28.6 to
46.2), including in 4 (3.2%) who had a complete response and in 42 (33.9%) who
had a partial response. The median duration of response was 11.1 months (95%
CI, 6.9 to could not be evaluated). Disease control occurred in 100 patients (80.6%;
95% CI, 72.6 to 87.2). The median progression-free survival was 6.8 months (95%
CI, 5.1 to 8.2), and the median overall survival was 12.5 months (95% CI, 10.0 to
could not be evaluated). Treatment-related adverse events occurred in 88 of 126
patients (69.8%), including grade 3 events in 25 patients (19.8%) and a grade 4
event in 1 (0.8%). Responses were observed in subgroups defined according to
PD-L1 expression, tumor mutational burden, and co-occurring mutations in
STK11, KEAP1, or TP53.
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CONCLUSIONS

In this phase 2 trial, sotorasib therapy led to a durable clinical benefit without new
safety signals in patients with previously treated KRAS p.G12C–mutated NSCLC.
(Funded by Amgen and the National Institutes of Health; CodeBreaK100 ClinicalTrials.gov number, NCT03600883.)
n engl j med 384;25
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onsiderable progress has been
made in the treatment of non–small-cell
lung cancer (NSCLC) in recent years, with
a substantial reduction in mortality.1,2 This progress is attributable largely to improvements in
systemic therapy for advanced disease, including
the approvals of targeted therapies for patients
with specific oncogenic driver mutations and of
checkpoint inhibitors, either as monotherapy or
in combination with chemotherapy, for patients
without an actionable driver mutation.3-6 However, the prognosis in patients with advanced
NSCLC receiving second or subsequent lines of
therapy is unsatisfactory, with 6 to 20% of such
patients having a response and with a median
progression-free survival of 2 to 4 months associated with chemotherapy agents or checkpoint
inhibitors.7-10 For patients whose disease progresses after the use of platinum-based chemotherapy and checkpoint inhibitors, chemotherapy
with docetaxel, with or without antiangiogenic
therapy, or single-agent pemetrexed remains the
standard care.11,12
Activating mutations in Kirsten rat sarcoma
viral oncogene homologue (KRAS) are found in
25 to 30% of non–squamous-cell NSCLCs, representing the most prevalent genomic driver event
in NSCLC.13-15 KRAS-mutated NSCLCs constitute
a molecularly diverse and clinically heterogeneous
group, and standard treatment options provide
only modest clinical benefit.16-18 Among all KRAS
mutations, the KRAS p.G12C single-nucleotide
variation, with glycine substituted by cysteine at
codon 12, is the most frequent variant in NSCLC,
with a prevalence of approximately 13% in lung
adenocarcinomas.13
The KRAS protein is a guanosine triphosphatase (GTPase) that serves as a molecular switch
by cycling between active guanosine triphosphate
(GTP)–bound and inactive guanosine diphosphate
(GDP)–bound states in response to extracellular
stimuli. The KRAS p.G12C mutation favors the
active form of KRAS and results in abnormally
high concentrations of GTP-bound KRAS, leading to hyperactivation of downstream oncogenic
pathways and uncontrolled cell growth.19 The
picomolar affinity of KRAS for GTP and the
high intracellular concentration of this trinucleo
tide, coupled with the lack of binding pockets on
GTP-bound KRAS and the consequent failure of
direct KRAS-targeting approaches, led to a longstanding notion that mutant KRAS is “undruggable.”20 This view persisted for almost four den engl j med 384;25
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cades until several breakthrough structural and
mechanistic studies established the conceptual
foundation for the clinical development of covalent and selective KRASG12C inhibitors.19,21-23
Sotorasib is a small molecule that specifically
and irreversibly inhibits KRASG12C. Sotorasib covalently binds to a pocket of the switch II region
that is present only in the inactive GDP-bound
conformation, trapping KRASG12C in the inactive
state and inhibiting KRAS oncogenic signaling.24
The phase 1 portion of the CodeBreaK100 trial,
which involved patients with pretreated advanced
solid tumors harboring the KRAS p.G12C mutation, showed encouraging safety and efficacy of
sotorasib monotherapy, and particularly promising
anticancer activity was observed in the subgroup
of patients with NSCLC.25 Here, we report results
from the phase 2 portion of the CodeBreaK100
trial (aimed at defining a particular indication for
use), which involved patients with KRAS p.G12C–
mutated advanced NSCLC. The phase 1 cohorts
and the phase 2 portion were analyzed separately; therefore, data from the patients in the
phase 1 cohorts are not included in the current
article.

Me thods
Patients

We conducted a multicenter, single-group, openlabel, phase 2 trial to evaluate the efficacy and
safety of sotorasib as monotherapy in patients with
locally advanced or metastatic KRAS p.G12C–
mutated NSCLC. Key inclusion criteria for this
trial were an age of 18 years or older; pathologically documented, locally advanced or metastatic
NSCLC with the KRAS p.G12C mutation confirmed on central laboratory testing with the use
of the therascreen KRAS RGQ PCR Kit; disease
progression after the receipt of anti–programmed death 1 (PD-1) or anti–programmed
death ligand 1 (PD-L1) immunotherapy or platinum-based combination chemotherapy or after
the receipt of both immunotherapy and platinumbased combination chemotherapy; an Eastern
Cooperative Oncology Group performance-status
score of 0 to 1 (on a scale from 0 to 5, with
higher numbers indicating greater disability); and
measurable disease according to the Response
Evaluation Criteria in Solid Tumors (RECIST),
version 1.1.
Key exclusion criteria were active untreated
brain metastases, the receipt of more than three
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previous lines of therapy, the receipt of systemic
anticancer therapy within 28 days before the
initiation of sotorasib therapy, the receipt of
therapeutic or palliative radiation therapy within
2 weeks before the initiation of sotorasib therapy,
and previous treatment with a direct KRASG12C
inhibitor. The full inclusion and exclusion criteria are listed in the protocol, available with the
full text of this article at NEJM.org.

regulatory authorities of participating countries.
All the patients provided written informed consent. The trial was designed by employees of
Amgen (the main sponsor) in collaboration with
the investigators. The data were collected by investigators, assessed by independent central review, and analyzed by statisticians employed by
Amgen. A medical writer employed by Amgen
wrote the first draft of the manuscript and provided editorial assistance. All the authors contribTrial Design and End Points
uted to the interpretation of the data and to the
Sotorasib was administered at a dose of 960 mg preparation of the manuscript. The authors vouch
orally once daily. Treatment with sotorasib con- for the completeness and accuracy of the data
tinued until the occurrence of progressive dis- and for the fidelity of the trial to the protocol.
ease, the development of unacceptable side efStatistical Analysis
fects, or withdrawal of consent.
The primary end point was objective response We planned that the phase 2 portion of this
(complete or partial response) as assessed by trial would include 105 patients with NSCLC. We
blinded, independent, central radiologic review. calculated that this sample size would provide
Tumor response was assessed by independent the trial with approximately 90% probability that
central review according to RECIST, version 1.1, the lower limit of the 95% confidence interval
with the use of contrast-enhanced computed for objective response would exceed the benchtomography or magnetic resonance imaging.
mark response of 23% among patients with preKey secondary end points were duration of treated NSCLC. This benchmark was shown in
response, disease control (defined as complete the phase 3 REVEL trial, which tested the comresponse, partial response, or stable disease, ac- bination of ramucirumab plus docetaxel as secondcording to RECIST, version 1.1; minimum time line treatment in patients with advanced NSCLC
interval for the determination of stable disease, after disease progression during platinum-based
5 weeks), time to response, progression-free sur- therapy.26
vival, overall survival, and safety. Adverse events
A data review team continuously assessed
were graded with the use of the Common Termi- safety and made recommendations to the main
nology Criteria for Adverse Events, version 5.0. sponsor regarding the continuation of the trial.
In accordance with the protocol, response-related The data review team also oversaw futility
end points were evaluated in patients who had analyses that were conducted in a continuous
received at least one dose of sotorasib and had at manner with the use of Bayesian predictive
least one measurable lesion at baseline as as- probability, starting after 25 patients completed
sessed by independent central review according to 7 weeks of the trial and occurring after every 10
RECIST, version 1.1. In the exploratory analyses, additional patients could be evaluated for recandidate biomarkers were evaluated by means sponse after completing at least 7 weeks of the
of molecular analysis of blood and tumor-tissue trial. The criterion for moving forward with the
specimens for their association with tumor re- trial was at least an 80% probability that the true
sponse to sotorasib therapy. Further details are response rate would exceed the benchmark. Fuincluded in the Supplementary Methods sec- tility was met if, with the enrollment of the
tion in the Supplementary Appendix, available at planned sample, the probability of reaching the
criterion was less than 5%.
NEJM.org.
Response was summarized with the use of
Trial Oversight
frequency counts and percentages, with exact
The trial was conducted in accordance with the 95% confidence intervals calculated by the ClopGood Clinical Practice guidelines of the Interna- per–Pearson method. Descriptive summaries of
tional Council for Harmonisation and the princi- the percentages of patients with a response and
ples of the Declaration of Helsinki. The protocol 95% Clopper–Pearson exact confidence intervals
and amendments were approved by the institu- according to biomarker subgroup are provided.
tional review board at each participating site and Time-to-event end points were summarized with
n engl j med 384;25
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Female sex — no. (%)

Patients
(N = 126)
63.5 (37–80)
63 (50.0)

Race — no. (%)†
White

103 (81.7)

Asian

19 (15.1)

Black

2 (1.6)

Other

2 (1.6)

Smoking history — no. (%)
Never smoked

6 (4.8)

Current smoker

15 (11.9)

Former smoker

102 (81.0)

Missing data

3 (2.4)

ECOG performance-status score — no. (%)‡
0

38 (30.2)

1

88 (69.8)

Brain metastasis — no. (%)
Yes

26 (20.6)

No

100 (79.4)

Histologic subtype — no. (%)
Squamous-cell carcinoma
Adenocarcinoma

1 (0.8)
120 (95.2)

Large-cell carcinoma

3 (2.4)

Bronchoalveolar carcinoma

2 (1.6)

Metastatic disease — no. (%)
Yes

122 (96.8)

No

4 (3.2)

No. of previous lines of anticancer systemic therapy —
no. (%)
1

54 (42.9)

2

44 (34.9)

3

28 (22.2)

Type of previous systemic anticancer therapy — no. (%)
Chemotherapy§

115 (91.3)

Platinum-based chemotherapy

113 (89.7)

Checkpoint inhibitor

116 (92.1)

Anti–PD-1 or anti–PD-L1 agent

115 (91.3)

Platinum-based chemotherapy and PD-1 or PD-L1
inhibitor

102 (81.0)

Antiangiogenic monoclonal antibodies

25 (19.8)

Targeted small molecules¶

9 (7.1)

Other‖

1 (0.8)

*	Percentages may not total 100 because of rounding. PD-1 denotes programmed
death 1, and PD-L1 programmed death ligand 1.
†	Race was reported by the patient.
‡	Performance-status scores on the Eastern Cooperative Oncology Group (ECOG)
scale range from 0 to 5, with higher numbers indicating greater disability.
§	Two patients who did not receive platinum-based chemotherapy received
pemetrexed, docetaxel, gemcitabine, and vinorelbine.
¶	Targeted small molecules included capmatinib, nintedanib, trametinib, voro‑
lanib, RMC-4630, sitravatinib, and cobimetinib.
‖	The other previous anticancer systemic therapy was an investigational agent.
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the use of Kaplan–Meier estimates and 95%
confidence intervals.

Table 1. Characteristics of the Patients at Baseline.*
Characteristic
Median age (range) — yr

of

n engl j med 384;25

R e sult s
Patients

A total of 126 patients with previously treated
KRAS p.G12C–mutated NSCLC were enrolled
from August 13, 2019, to February 5, 2020, and
received at least one dose of sotorasib. According
to independent central review, 2 patients did not
have measurable lesions at baseline and were
ineligible for response assessment. Among the
remaining 124 patients, 1 did not have centrally
confirmed KRAS p.G12C mutation; this patient
had stable disease and was included in the response assessments as prespecified in the protocol.
The data-cutoff date was March 15, 2021. The
median follow-up was 15.3 months (range, 1.1
to 18.4+; the plus sign indicates that the value
includes data that were censored at data cutoff).
The median duration of treatment was 5.5 months
(range, 0.2 to 17.8). A total of 88 patients (69.8%)
received sotorasib for 3 months or more, 60
(47.6%) for 6 months or more, and 41 (32.5%) for
9 months or more. Dose reduction occurred in
26 patients (20.6%). As of the data-cutoff date,
103 patients (81.7%) had discontinued treatment
with sotorasib; disease progression (in 83 patients [65.9%]) and adverse events regardless of
attribution (in 11 [8.7%]) were the most common reasons for discontinuation (Fig. S1 in the
Supplementary Appendix).
The characteristics of the patients at baseline
are summarized in Table 1, with further details
provided in Table S1. Among the 126 enrolled
patients, the median age was 63.5 years (range,
37 to 80), and 117 (92.9%) were current or former smokers. Patients had received a median of
two previous lines of systemic anticancer therapy. Previous therapies included platinum-based
chemotherapy (in 113 patients [89.7%]), checkpoint inhibitors (in 116 [92.1%]), and antiangiogenic therapies (in 25 [19.8%]). A total of 102 patients (81.0%) had received both platinum-based
chemotherapy and a PD-1 or PD-L1 inhibitor.
Efficacy

Among the 124 patients who were evaluated for
a response, 4 (3.2%) had a complete response
and 42 (33.9%) had a partial response; thus, an
objective response occurred in 46 patients (37.1%;
nejm.org
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95% confidence interval [CI], 28.6 to 46.2). Disease control occurred in 100 patients (80.6%;
95% CI, 72.6 to 87.2) (Table 2). Tumor shrinkage
of any magnitude was observed in 102 patients
(82.3%); among all the patients who had a response, the median best percentage decrease
from baseline in tumor burden (defined as the
sum of the longest diameters of all target lesions) was 60% (Fig. 1A). Disease progression
was the best overall response in 20 patients. A
total of 4 patients either could not be evaluated
for a response (2) or had missing scans (2). Percentages of patients with an objective response
were consistent across prespecified subgroups
defined according to the number of previous lines
of therapy and according to previous receipt of
anti–PD-1 or anti–PD-L1 therapy (Table S2).
Among the 46 patients with an objective response, the median time to response was 1.4
months (range, 1.2 to 10.1), and the median
duration of response was 11.1 months (95% CI,
6.9 to could not be evaluated). A response was
observed at the first tumor assessment, at approximately week 6, in 33 patients (71.7%) with
a response. As of the data-cutoff date, 16 patients with a response (34.7%) were continuing
to receive treatment without disease progression
(Fig. 1B). Among patients with a response, the
Kaplan–Meier estimate of duration of response
was 90.5% (95% CI, 76.7 to 96.3) at 3 months,
70.8% (95% CI, 54.3 to 82.2) at 6 months, and
57.3% (95% CI, 40.4 to 71.0) at 9 months.
The median progression-free survival among
the 124 patients who could be evaluated was 6.8
months (95% CI, 5.1 to 8.2) (Fig. 1C). The Kaplan–
Meier estimate of progression-free survival was
52.2% (95% CI, 42.6 to 60.9) at 6 months and
37.5% (95% CI, 28.4 to 46.5) at 9 months. The
median overall survival among all 126 enrolled
patients was 12.5 months (95% CI, 10.0 to could
not be evaluated) (Fig. 1D). In an analysis of response according to assessment by the local investigator, which included all 126 patients, 2 patients (1.6%) had a complete response, 37 (29.4%)
had a partial response, 69 (54.8%) had stable
disease, and 15 (11.9%) had disease progression
(Table S3).
Exploratory Biomarkers

In the descriptive exploratory analyses, we evaluated the potential association between response
to sotorasib therapy and baseline tumor PD-L1
expression level, tumor mutational burden, and
n engl j med 384;25

Table 2. Tumor Response to Sotorasib Therapy According to Independent
Central Review.*
Patients
(N = 124)

Variable
Objective response — % (95% CI)†

37.1 (28.6–46.2)

Disease control — % (95% CI)‡

80.6 (72.6–87.2)

Best response — no. (%)
Complete response

4 (3.2)

Partial response

42 (33.9)

Stable disease

54 (43.5)

Progressive disease

20 (16.1)

Could not be evaluated

2 (1.6)

Missing scan

2 (1.6)

Median duration of objective response (95% CI)
— mo§

11.1 (6.9–NE)

Kaplan–Meier estimate of objective response
(95% CI) — %
At 3 mo

90.5 (76.7–96.3)

At 6 mo

70.8 (54.3–82.2)

At 9 mo

57.3 (40.4–71.0)

*	NE denotes could not be evaluated.
†	Objective response was defined as a complete or partial response.
‡	Disease control was defined as a complete response, partial response, or stable
disease.
§	The median duration of objective response was calculated on the basis of the
46 patients who had a complete or partial response.

mutations in STK11, KEAP1, and TP53, which are
among the most prevalent genes with co-occurring mutations in KRAS-mutated NSCLC (Figs. 2,
S2, and S3 and Tables S6 and S7).27 Among the
86 patients who were assessed for PD-L1 expression, objective response and tumor shrinkage were
observed across the range of baseline PD-L1 expression levels, with 48% (95% CI, 32 to 63) of
the patients in the PD-L1–negative group (tumor
proportion score, <1%) having a response, as
well as 42% (95% CI, 31 to 53) of the overall
population of patients who could be evaluated
(Fig. 2A). Among the 84 patients who were assessed for tumor mutational burden, a response
was seen in 42% (95% CI, 30 to 55) of the patients in the subgroup with a low tumor mutational burden (<10 mutations per megabase) and
in 40% (95% CI, 16 to 68) of those in the subgroup with a high tumor mutational burden
(≥10 mutations per megabase) (Table S7).
Among the 104 patients who were assessed
for co-occurring genomic alterations, efficacy
was seen in the subgroups with mutated STK11,
KEAP1, or TP53 (Fig. 2B). A response was seen in
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A Best Percentage Change in Tumor Burden

Best Percentage Change
from Baseline (%)
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Stable disease

Partial response

Complete response
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B Time to Response and Duration of Response in 46 Patients
Patients with a Response to Sotorasib
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events were diarrhea (in 40 patients [31.7%]),
nausea (in 24 [19.0%]), increase in the alanine
aminotransferase level (in 19 [15.1%]), increase
in the aspartate aminotransferase level (in 19
[15.1%]), and fatigue (in 14 [11.1%]). Treatmentrelated adverse events led to dose modification
(dose interruption, reduction, or both) in 28 patients (22.2%) and to the discontinuation of
therapy in 9 (7.1%). The most common treatment-related adverse events that led to dose
modification were diarrhea (in 10 patients
[7.9%]), increase in the aspartate aminotransferase level (in 10 [7.9%]), increase in the alanine
aminotransferase level (in 9 [7.1%]), increase in
the blood alkaline phosphatase level (in 3 [2.4%]),
and nausea (in 3 [2.4%]).

Figure 1 (facing page). Efficacy of Sotorasib Therapy.
Panel A shows the best percentage decrease from base‑
line in the tumor burden (defined as the sum of the lon‑
gest diameters of all target lesions) in 121 of 124 patients
with non–small-cell lung cancer who had available post‑
baseline measurements of target lesions. The 3 patients
whose data were excluded from the graph include 2 who
had missing scans and 1 who had no measurement in
target lesions and had progressive disease in nontarget
lesions (progressive disease as the best overall response).
Panel B shows the time to response, duration of response,
and patient status as of the data-cutoff date for all 46
patients who had an objective response to sotorasib
therapy. Panel C shows the Kaplan–Meier curve of pro‑
gression-free survival among all 124 patients who could
be evaluated for a response according to central review.
Panel D shows the Kaplan–Meier curve of overall sur‑
vival among all 126 patients enrolled in the trial. Tick
marks in Panels C and D indicate censored data.

50% (95% CI, 28 to 72) of the patients in the
subgroup with mutated STK11 and wild-type
KEAP1 and in 39% (95% CI, 30 to 49) of the
overall population of patients who could be
evaluated. Among patients with mutated KEAP1,
a response was seen in 23% (95% CI, 5 to 54) of
those in the subgroup with both mutated STK11
and KEAP1 and in 14% (95% CI, 0 to 58) of those
in the subgroup with wild-type STK11 and mutated KEAP1 (Fig. 2C).
Safety

Safety data for all 126 patients are summarized
in Tables 3, S4, and S5. Adverse events of any
grade, regardless of attribution, were observed
in 125 patients (99.2%); the most common adverse events were diarrhea (in 64 patients
[50.8%]), nausea (in 39 [31.0%]), fatigue (in 32
[25.4%]), arthralgia (in 27 [21.4%]), increase in
the aspartate aminotransferase level (in 27
[21.4%]), and increase in the alanine aminotransferase level (in 26 [20.6%]). The worst grade
of adverse event was grade 3 in 53 patients
(42.1%), grade 4 in 4 patients (3.2%), and grade
5 in 20 patients (15.9%).
A total of 88 patients (69.8%) reported adverse events of any grade that were considered
by the investigators to be related to treatment
(treatment-related adverse events). The worst grade
of treatment-related adverse event was grade 3 in
25 patients (19.8%) and grade 4 in 1 patient
(0.8%; pneumonitis and dyspnea); no treatmentrelated adverse events of grade 5 were reported.
The most frequent treatment-related adverse
n engl j med 384;25

Discussion
The highly selective and irreversible KRASG12C
inhibitor sotorasib showed clinical efficacy with
reversible toxic effects, mainly of grade 1 or 2,
in the phase 1 portion of the CodeBreaK100
trial.25 In the NSCLC cohort of the current phase
2 portion of this trial, an objective response was
observed in 37.1% of the patients, with a median
duration of response of 11.1 months. The median progression-free survival was 6.8 months,
and the median overall survival was 12.5 months.
In addition, tumor shrinkage and disease control were observed in the majority of patients.
These data provide further evidence in support
of the clinical use of sotorasib in patients with
KRAS p.G12C–mutated NSCLC.
With the incorporation of immunotherapies
into the first-line treatment of advanced NSCLC,
the current standard care for patients with newly
diagnosed KRAS-mutated NSCLC commonly involves an immune-checkpoint inhibitor, either in
combination with chemotherapy or as monotherapy.4-6 However, for patients whose disease
progresses after immunotherapy and platinum
doublet chemotherapy, few effective second-line
options are available. Single-agent chemotherapy
with pemetrexed or docetaxel, a standard care in
this context, yields unsatisfactory outcomes,
with less than 10% of patients having a response
and with a median progression-free survival of
less than 4 months.12,17,18,26 Survival was longer
with the addition of ramucirumab (antibody to
vascular endothelial growth factor receptor 2) or
nintedanib (a broadly acting receptor tyrosine
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Figure 2. Exploratory Biomarker Analyses.
Panel A shows the percentages of patients with an ob‑
jective response associated with sotorasib therapy in
subgroups categorized according to programmed
death ligand 1 (PD-L1) expression level. A total of 86
patients with available tissue data were evaluated. Pan‑
el B shows the percentages of patients with an objec‑
tive response in subgroups categorized according to
the mutational status of TP53, STK11, and KEAP1, and
Panel C the percentages of patients with an objective
response in subgroups categorized according to the
mutational status of STK11 and KEAP1. In these analy‑
ses, 104 patients with available tissue data, plasma
data, or both were evaluated. In all panels, I bars rep‑
resent 95% confidence intervals.

kinase inhibitor) to docetaxel therapy than with
the use of docetaxel alone in the REVEL trial and
the LUME–Lung 1 trial, respectively.26,28 Combination therapy with ramucirumab plus docetaxel
led to a median progression-free survival of 4.5
months and to a response in 23% of the patients, a percentage that was used as the benchmark response in this trial of sotorasib.26 In our
trial, the majority of the patients (81.0%) had
advanced NSCLC that had been previously treated with both checkpoint inhibitors and platinumbased chemotherapy; nonetheless, sotorasib treatment induced rapid and durable responses that
were also observed across all PD-L1 expression
level subgroups. Although it is not possible to
compare results across different trials, the efficacy that was associated with sotorasib therapy
appears to exceed that with ramucirumab plus
docetaxel, which was previously reported in the
REVEL trial (i.e., the lower boundary of the 95%
confidence interval for objective response exceeded that for the benchmark response), and
improved outcomes in this population of patients.
The percentage of patients with an objective
response that was associated with sotorasib
therapy in our trial appears to be lower than that
associated with tyrosine kinase inhibitors that
have been approved for the treatment of NSCLCs
with targetable driver mutations. This finding
could potentially be attributable to the inherent
molecular heterogeneity of KRAS-mutated tumors,
which may predispose tumors to adapt quickly
to the selective pressure of KRASG12C inhibition.29,30 In addition, the genome damage that
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Table 3. Adverse Events.*
Event

All Patients (N = 126)
Any Grade

Grade 1 or 2

125 (99.2)

48 (38.1)

Treatment-related adverse event

88 (69.8)

Treatment-related adverse event leading to
dose modification

28 (22.2)

Grade 3

Grade 4

Fatal

53 (42.1)

4 (3.2)

20 (15.9)

62 (49.2)

25 (19.8)

1 (0.8)

0

8 (6.3)

20 (15.9)

0

0

9 (7.1)

4 (3.2)

4 (3.2)

1 (0.8)

0

Diarrhea

40 (31.7)

35 (27.8)

5 (4.0)

0

0

Nausea

24 (19.0)

24 (19.0)

0

0

0

Alanine aminotransferase increase

19 (15.1)

11 (8.7)

8 (6.3)

0

0

Aspartate aminotransferase increase

19 (15.1)

12 (9.5)

7 (5.6)

0

0

Fatigue

14 (11.1)

14 (11.1)

0

0

0

Vomiting

10 (7.9)

10 (7.9)

0

0

0

Blood alkaline phosphatase increase

9 (7.1)

8 (6.3)

1 (0.8)

0

0

Maculopapular rash

7 (5.6)

7 (5.6)

0

0

0

Hypokalemia

5 (4.0)

4 (3.2)

1 (0.8)

0

0

Drug-induced liver injury

3 (2.4)

1 (0.8)

2 (1.6)

0

0

γ-Glutamyltransferase increase

3 (2.4)

0

3 (2.4)

0

0

Lymphocyte count decrease

3 (2.4)

2 (1.6)

1 (0.8)

0

0

Dyspnea

2 (1.6)

1 (0.8)

0

1 (0.8)

0

Pneumonitis

2 (1.6)

0

1 (0.8)

1 (0.8)

0

Abnormal hepatic function

2 (1.6)

1 (0.8)

1 (0.8)

0

0

Lymphopenia

1 (0.8)

0

1 (0.8)

0

0

Neutropenia

1 (0.8)

0

1 (0.8)

0

0

Hepatotoxic event

1 (0.8)

0

1 (0.8)

0

0

Drug hypersensitivity

1 (0.8)

0

1 (0.8)

0

0

Cellulitis

1 (0.8)

0

1 (0.8)

0

0

Lipase increased

1 (0.8)

0

1 (0.8)

0

0

Increase in liver-function level†

1 (0.8)

0

1 (0.8)

0

0

Neutrophil count decrease

1 (0.8)

0

1 (0.8)

0

0

Abnormal aminotransferase level‡

1 (0.8)

0

1 (0.8)

0

0

number of patients (percent)
Adverse event

Treatment-related adverse event leading to dis‑
continuation of therapy
Treatment-related adverse event of any grade
occurring in >5% of the patients or that
was grade ≥3

*	For patients who had an adverse event of multiple grades, the worst grade is reported. Adverse events were graded
with the use of the Common Terminology Criteria for Adverse Events, version 5.0, which incorporates certain elements
of Medical Dictionary for Regulatory Activities (MedDRA) terminology.
†	The MedDRA preferred term “increased liver-function test” was used for this event.
‡	The MedDRA preferred term “transaminases abnormal” was used for this event.

has been associated with tobacco carcinogens drive tumor growth.31 Future investigations are
and that is commonly seen with KRAS p.G12C expected to shed light on mechanisms of adapmutations may provide alternative pathways to tation or resistance, as well as to inform the
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development of combination strategies to enhance the anticancer activity of KRASG12C inhibitors. Given that patients with active untreated
brain metastases were excluded from this trial,
the efficacy of sotorasib in the treatment of patients with central nervous system metastases
remains to be further investigated.
Co-occurring genomic alterations in KRASmutated tumors have an effect on the tumor
biology and response to systemic therapies.16,32,33
In our exploratory analyses, the activity of sotorasib was observed across a spectrum of prevalent
co-occurring mutations, including STK11 and
KEAP1, both of which are associated with inferior treatment outcomes and a poor prognosis in
patients with NSCLC.18,27,33-37 A numerically higher
response was seen among patients with STK11mutated tumors that were wild-type for KEAP1
than in other subgroups or among all patients
who could be evaluated. This finding is noteworthy because inactivating genomic alterations
in STK11 confer primary resistance to PD-1 and
PD-L1 blockade and docetaxel in patients with
KRAS-mutated NSCLC.18,33 A response to sotorasib therapy was also observed in patients with
KEAP1-mutated tumors, although at a lower percentage than among patients with wild-type
KEAP1. These exploratory analyses were not statistically powered, and the 95% confidence intervals overlap across subgroups; therefore, the
results should be interpreted with caution. Future prospective studies are warranted to iden-

of

m e dic i n e

tify subgroups of patients who may benefit differently from sotorasib therapy.
In a result that was consistent with the safety
findings of the phase 1 study, treatment with
sotorasib produced primarily grade 1 and 2 side
effects in this trial, mainly low-grade hepatic
and gastrointestinal toxic effects, and there were
no new safety signals. The percentages of patients who had a dose modification or who discontinued treatment were low, with only 7.1% of
patients discontinuing treatment.
In the phase 2 portion of this trial, sotorasib
therapy led to a rapid and durable clinical benefit
in patients with KRAS p.G12C–mutated NSCLC.
A phase 3 trial to compare sotorasib therapy
with docetaxel therapy in patients with previously treated, locally advanced, unresectable or
metastatic NSCLC with a KRAS p.G12C mutation
is under way (CodeBreaK200 ClinicalTrials.gov
number, NCT04303780). In addition, efforts are
ongoing to investigate sotorasib in combination
therapies (CodeBreaK101; NCT04185883) and to
identify patients who may benefit from sotorasib
regimens in the context of first-line treatment.
Supported by Amgen and by a Cancer Center Core Grant (P30
CA008748, to Dr. Li) at Memorial Sloan Kettering Cancer Center
from the National Institutes of Health.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
A data sharing statement provided by the authors is available
with the full text of this article at NEJM.org.
We thank the patients and their families for participating in
this trial and Yang Li (of Amgen) for medical writing assistance
with an earlier version of the manuscript.

Appendix
The authors’ full names and academic degrees are as follows: Ferdinandos Skoulidis, M.D., Ph.D., Bob T. Li, M.D., Ph.D., M.P.H.,
Grace K. Dy, M.D., Timothy J. Price, M.B., B.S., D.H.Sc., Gerald S. Falchook, M.D., Jürgen Wolf, M.D., Antoine Italiano, M.D., Martin
Schuler, M.D., Hossein Borghaei, D.O., Fabrice Barlesi, M.D., Ph.D., Terufumi Kato, M.D., Alessandra Curioni‑Fontecedro, M.D.,
Adrian Sacher, M.D., Alexander Spira, M.D., Ph.D., Suresh S. Ramalingam, M.D., Toshiaki Takahashi, M.D., Ph.D., Benjamin Besse,
M.D., Ph.D., Abraham Anderson, Ph.D., Agnes Ang, Ph.D., Qui Tran, Ph.D., Omar Mather, M.D., Haby Henary, M.D., Gataree Ngarmchamnanrith, M.D., Gregory Friberg, M.D., Vamsidhar Velcheti, M.D., and Ramaswamy Govindan, M.D.
The authors’ affiliations are as follows: the University of Texas M.D. Anderson Cancer Center, Houston (F.S.), and U.S. Oncology
Research, the Woodlands (A. Spira) — both in Texas; Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine (B.T.L.) and
Thoracic Medical Oncology, Perlmutter Cancer Center, New York University (V.V.), New York, and Roswell Park Cancer Institute, Buffalo (G.K.D.) — all in New York; the Queen Elizabeth Hospital and University of Adelaide, Woodville, SA, Australia (T.J.P.); Sarah
Cannon Research Institute at HealthONE, Denver (G.S.F.); Department I of Internal Medicine, Center for Integrated Oncology, University Hospital Cologne, Cologne (J.W.), the West German Cancer Center, University Hospital Essen, University Duisburg–Essen, Essen
(M.S.), and the German Cancer Consortium, Heidelberg (M.S.) — all in Germany; the Early Phase Trials and Sarcoma Units, Bergonie
Cancer Institute, Bordeaux (A.I.), and Gustave Roussy Institute, Villejuif (F.B., B.B.) — both in France; Fox Chase Cancer Center,
Philadelphia (H.B.); Kanagawa Cancer Center, Yokohama (T.K.), and the Division of Thoracic Oncology, Shizuoka Cancer Center,
Shizuoka (T.T.) — both in Japan; the Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland
(A.C.-F.); Princess Margaret Cancer Centre, University Health Network, Toronto (A. Sacher); Virginia Cancer Specialists, Fairfax
(A. Spira); Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore (A. Spira); Winship Cancer Institute of Emory
University, Atlanta (S.S.R.); Amgen, Thousand Oaks, CA (A. Anderson, A. Ang, Q.T., O.M., H.H., G.N., G.F.); and the Alvin J. Siteman
Cancer Center, Washington University School of Medicine, St. Louis (R.G.).

2380

n engl j med 384;25

nejm.org

June 24, 2021

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on January 6, 2022. For personal use only. No other uses without permission.
Copyright © 2021 Massachusetts Medical Society. All rights reserved.

Sotor asib for Lung Cancers with KR AS p.G12C Mutation

References
1. Howlader N, Forjaz G, Mooradian MJ,
et al. The effect of advances in lung-cancer
treatment on population mortality. N Engl
J Med 2020;383:640-9.
2. Siegel RL, Miller KD, Fuchs HE, Jemal
A. Cancer statistics, 2021. CA Cancer J
Clin 2021;71:7-33.
3. Black RC, Khurshid H. NSCLC: an update of driver mutations, their role in
pathogenesis and clinical significance.
R I Med J (2013) 2015;98:25-8.
4. Gandhi L, Rodríguez-Abreu D, Gadgeel
S, et al. Pembrolizumab plus chemother
apy in metastatic non–small-cell lung
cancer. N Engl J Med 2018;378:2078-92.
5. Mok TSK, Wu Y-L, Kudaba I, et al.
Pembrolizumab versus chemotherapy for
previously untreated, PD-L1-expressing,
locally advanced or metastatic non-smallcell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3
trial. Lancet 2019;393:1819-30.
6. Carbone DP, Reck M, Paz-Ares L, et al.
First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. N Engl J
Med 2017;376:2415-26.
7. Borghaei H, Paz-Ares L, Horn L, et al.
Nivolumab versus docetaxel in advanced
nonsquamous non–small-cell lung cancer. N Engl J Med 2015;373:1627-39.
8. Herbst RS, Baas P, Kim D-W, et al.
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced
non-small-cell lung cancer (KEYNOTE-010):
a randomised controlled trial. Lancet 2016;
387:1540-50.
9. Rittmeyer A, Barlesi F, Waterkamp D,
et al. Atezolizumab versus docetaxel in
patients with previously treated nonsmall-cell lung cancer (OAK): a phase 3,
open-label, multicentre randomised controlled trial. Lancet 2017;389:255-65.
10. Pallis AG, Agelaki S, Agelidou A, et al.
A randomized phase III study of the
docetaxel/carboplatin combination versus
docetaxel single-agent as second line
treatment for patients with advanced/
metastatic non-small cell lung cancer.
BMC Cancer 2010;10:633.
11. Shepherd FA, Dancey J, Ramlau R,
et al. Prospective randomized trial of
docetaxel versus best supportive care in
patients with non-small-cell lung cancer
previously treated with platinum-based
chemotherapy. J Clin Oncol 2000;18:2095103.
12. Hanna N, Shepherd FA, Fossella FV,
et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with
non-small-cell lung cancer previously
treated with chemotherapy. J Clin Oncol
2004;22:1589-97.
13. Biernacka A, Tsongalis PD, Peterson
JD, et al. The potential utility of re-mining
results of somatic mutation testing:

KRAS status in lung adenocarcinoma.
Cancer Genet 2016;209:195-8.
14. Riely GJ, Kris MG, Rosenbaum D,
et al. Frequency and distinctive spectrum
of KRAS mutations in never smokers with
lung adenocarcinoma. Clin Cancer Res
2008;14:5731-4.
15. Boch C, Kollmeier J, Roth A, et al. The
frequency of EGFR and KRAS mutations
in non-small cell lung cancer (NSCLC):
routine screening data for central Europe
from a cohort study. BMJ Open 2013;3(4):
e002560.
16. Skoulidis F, Byers LA, Diao L, et al.
Co-occurring genomic alterations define
major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. Cancer Discov 2015;5:860-77.
17. Jänne PA, van den Heuvel MM, Barlesi
F, et al. Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRASmutant advanced non-small cell lung
cancer: the SELECT-1 randomized clinical
trial. JAMA 2017;317:1844-53.
18. Singh A, Daemen A, Nickles D, et al.
NRF2 activation promotes aggressive lung
cancer and associates with poor clinical
outcomes. Clin Cancer Res 2021;27:87788.
19. Ostrem JM, Peters U, Sos ML, Wells
JA, Shokat KM. K-Ras(G12C) inhibitors
allosterically control GTP affinity and effector interactions. Nature 2013;503:54851.
20. Cox AD, Fesik SW, Kimmelman AC,
Luo J, Der CJ. Drugging the undruggable
RAS: mission possible? Nat Rev Drug Discov 2014;13:828-51.
21. Ostrem JM, Shokat KM. Direct smallmolecule inhibitors of KRAS: from structural insights to mechanism-based design. Nat Rev Drug Discov 2016;
15:
771-85.
22. Lito P, Solomon M, Li L-S, Hansen R,
Rosen N. Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping
mechanism. Science 2016;351:604-8.
23. Patricelli MP, Janes MR, Li L-S, et al.
Selective inhibition of oncogenic KRAS
output with small molecules targeting the
inactive state. Cancer Discov 2016;6:31629.
24. Canon J, Rex K, Saiki AY, et al. The
clinical KRAS(G12C) inhibitor AMG 510
drives anti-tumour immunity. Nature
2019;575:217-23.
25. Hong DS, Fakih MG, Strickler JH,
et al. KRASG12C inhibition with sotorasib
in advanced solid tumors. N Engl J Med
2020;383:1207-17.
26. Garon EB, Ciuleanu T-E, Arrieta O,
et al. Ramucirumab plus docetaxel versus
placebo plus docetaxel for second-line

n engl j med 384;25

nejm.org

treatment of stage IV non-small-cell lung
cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3
trial. Lancet 2014;384:665-73.
27. Arbour KC, Jordan E, Kim HR, et al.
Effects of co-occurring genomic alterations on outcomes in patients with KRASmutant non-small cell lung cancer. Clin
Cancer Res 2018;24:334-40.
28. Reck M, Kaiser R, Mellemgaard A,
et al. Docetaxel plus nintedanib versus
docetaxel plus placebo in patients with
previously treated non-small-cell lung
cancer (LUME-Lung 1): a phase 3, doubleblind, randomised controlled trial. Lancet
Oncol 2014;15:143-55.
29. Scheffler M, Ihle MA, Hein R, et al.
K-ras mutation subtypes in NSCLC and
associated co-occuring mutations in other
oncogenic pathways. J Thorac Oncol 2019;
14:606-16.
30. Xue JY, Zhao Y, Aronowitz J, et al.
Rapid non-uniform adaptation to conformation-specific KRAS(G12C) inhibition.
Nature 2020;577:421-5.
31. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS
mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to
smoking-related KRAS-mutant cancers.
Clin Cancer Res 2012;18:6169-77.
32. Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-smallcell lung cancer biology and therapy. Nat
Rev Cancer 2019;19:495-509.
33. Skoulidis F, Goldberg ME, Greenawalt
DM, et al. STK11/LKB1 mutations and PD-1
inhibitor resistance in KRAS-mutant lung
adenocarcinoma. Cancer Discov 2018;8:
822-35.
34. Negrao MV, Lam VK, Reuben A, et al.
PD-L1 expression, tumor mutational burden, and cancer gene mutations are stronger predictors of benefit from immune
checkpoint blockade than HLA class I
genotype in non-small cell lung cancer.
J Thorac Oncol 2019;14:1021-31.
35. Chen X, Su C, Ren S, Zhou C, Jiang T.
Pan-cancer analysis of KEAP1 mutations
as biomarkers for immunotherapy outcomes. Ann Transl Med 2020;8:141.
36. Jeong Y, Hellyer JA, Stehr H, et al. Role
of KEAP1/NFE2L2 mutations in the chemotherapeutic response of patients with
non-small cell lung cancer. Clin Cancer
Res 2020;26:274-81.
37. La Fleur L, Falk-Sörqvist E, Smeds P,
et al. Mutation patterns in a populationbased non-small cell lung cancer cohort
and prognostic impact of concomitant
mutations in KRAS and TP53 or STK11.
Lung Cancer 2019;130:50-8.
Copyright © 2021 Massachusetts Medical Society.

June 24, 2021

2381

The New England Journal of Medicine
Downloaded from nejm.org at Washington University in St. Louis Becker Library on January 6, 2022. For personal use only. No other uses without permission.
Copyright © 2021 Massachusetts Medical Society. All rights reserved.

